Trevena Faces Nasdaq Delisting and Uncertain OTC Future

Trevena ( (TRVN) ) has shared an update.

Trevena, Inc., a biopharmaceutical company, has been notified by the Nasdaq Hearings Panel of the impending delisting of its common stock from the Nasdaq due to non-compliance with the stockholder’s equity requirement. The company’s stock is expected to shift to the Pink Open Market following suspension on Nasdaq starting October 8, 2024. There is uncertainty about whether the stock will continue to be traded over-the-counter post-delisting.

For an in-depth examination of TRVN stock, go to TipRanks’ Stock Analysis page.